hu7DE7FD Frozen Validation Report
339 PRS models · 1,636 protein predictions · 135 candidate variants. This static snapshot is generated from the public report JSON artifact.
Overview-first report: suggested next steps are shown before technical PRS and protein tables. Genetic evidence is not diagnostic by itself.
Clinical Variant Status
✓No confirmed pathogenic
Glucose Handling With Lean-Body Counterweight
near-term focus
Your inherited pattern suggests stronger attention to blood-sugar stability than body size alone might imply. Several body-fat and lipid signals look favorable, so the useful focus is steady energy, muscle support, and real lab context rather than weight loss.
Full explanation
The glucose-related side of the evidence is strong: several inherited scores point toward higher glucose, insulin resistance, diabetes-related, and long-term blood-sugar traits.
At the same time, the body-composition side is not simply high-risk. Waist size, visceral fat, triglycerides, cholesterol, and body-mass signals lean favorable, while basal metabolic rate and some lean-mass signals lean low.
That combination is divergent. It suggests that a person could look lean or have favorable lipid tendencies while still benefiting from steady meals, strength training, and periodic real-world glucose markers if clinically appropriate.
This category becomes worth discussing if routine blood tests show elevated fasting glucose, long-term glucose, insulin resistance, unusual energy crashes, strong family history of diabetes, pregnancy-related glucose concerns, or unexplained changes in weight, appetite, thirst, or urination.
What to watch forUse stable meals, fiber-rich carbohydrates, protein at each meal, and progressive strength training; review this with a clinician if glucose labs, pregnancy context, family history, or persistent energy swings make it relevant.
Show technical evidence
Risk-score evidence
- glucose: risk percentile 97.9%, coverage 100%, PGS001952.
- diabetes: risk percentile 96.2%, coverage 90%, PGS001327.
- insulin resistance: risk percentile 88.7%, coverage 98%, PGS000877.
- glycated haemoglobin: risk percentile 87.7%, coverage 100%, PGS001953.
- overweight obesity and other hyperalimentation: risk percentile 92.6%, coverage 100%, PGS001825.
- waist circumference: risk percentile 0.1%, coverage 95%, PGS000828.
Protein pathway context
- VNN1: predicted level percentile 1%, R2 0.5856; pathway context only.
- FSHB: predicted level percentile 91.7%, R2 0.6068; pathway context only.
Candidate variants
- Variant rs10105606 CC: snpedia_context.
- Variant rs10503669 CC: snpedia_context.
- Variant rs103294 TT: snpedia_context.
Gut And Immune Inflammation Pattern
near-term focus
The strongest multi-lane theme is gut and immune sensitivity. The evidence points to inflammatory bowel, celiac, mouth-ulcer, immune-cell, and immune-signaling context, but not to a diagnosis by itself.
Full explanation
Several inherited scores cluster around gut and immune inflammation, including inflammatory bowel traits, celiac-related traits, mouth ulcers, intestinal malabsorption, and immune-cell balance.
The protein pathway evidence also points toward immune-cell communication, fungal-defense signaling, macrophage repair, natural-killer-cell recognition, and immune adhesion pathways. Individual inherited markers add autoimmune and inflammatory-trait context.
This does not mean inflammatory bowel disease, celiac disease, or an autoimmune condition is present. It means the inherited pattern is interesting enough that gut symptoms and immune history would matter more when interpreting the result.
This category becomes worth reviewing if there are persistent bowel changes, blood in stool, unexplained weight loss, recurring mouth ulcers, iron deficiency, long-running abdominal pain, gluten-related reactions, strong autoimmune family history, or abnormal inflammatory or nutrient labs.
What to watch forTreat this as a gut-and-immune awareness flag; seek medical review if persistent digestive symptoms, mouth ulcers, nutrient deficiencies, inflammatory markers, or autoimmune family history make it relevant.
Show technical evidence
Risk-score evidence
- ulcerative colitis: risk percentile 98.6%, coverage 100%, PGS001855.
- celiac disease: risk percentile 98.4%, coverage 100%, PGS001856.
- inflammatory bowel disease: risk percentile 92.4%, coverage 100%, PGS004013.
- crohn s disease: risk percentile 89.4%, coverage 83%, PGS001331.
- mouth ulcers: risk percentile 95.1%, coverage 90%, PGS000947.
- intestinal malabsorption: risk percentile 82.6%, coverage 88%, PGS000940.
Protein pathway context
- CLEC7A: predicted level percentile 98.7%, R2 0.5374; pathway context only.
- MST1: predicted level percentile 95.5%, R2 0.6781; pathway context only.
- CD33: predicted level percentile 94.4%, R2 0.7974; pathway context only.
- KIR3DL1: predicted level percentile 93.9%, R2 0.5981; pathway context only.
- CD70: predicted level percentile 92.5%, R2 0.5346; pathway context only.
- ICAM2: predicted level percentile 92.4%, R2 0.5536; pathway context only.
Candidate variants
- Variant rs10865331 GG: snpedia_context.
- Variant rs11117432 GG: snpedia_context.
- SQRDL rs1044032 TT: snpedia_context.
Mood, Attention, Sleep, And Reward Sensitivity
near-term focus
Inherited scores for attention, depression-related traits, anxiety-related care-seeking, sleep difficulty, foreboding, tobacco, and addiction-related tendencies cluster together. This is a sensitivity profile, not a statement that any symptom is present.
Full explanation
The brain-and-behavior evidence is broad and consistent. Several inherited scores point toward attention regulation, mood vulnerability, anxiety or tension-related care-seeking, sleep difficulty, and feelings of foreboding.
Reward and habit-related scores also appear, including tobacco-use and broader addiction-related context. A low alcohol-use-disorder score softens one part of the picture but does not remove the larger attention, mood, and sleep pattern.
Research-only brain-region scores are present too, but those are not medical conclusions. They are best used as background for a broader brain-wiring narrative.
This category becomes worth discussing if there is persistent low mood, anxiety, attention difficulty, insomnia, impulsive coping, increased substance cravings, major life stress, strong family history, or meaningful changes in work, study, relationships, or daily functioning.
What to watch forPrioritize consistent sleep timing, structured routines, exercise that improves mood without overtraining, and early support if mood, attention, sleep, or substance-use patterns start affecting daily life.
Show technical evidence
Risk-score evidence
- attention deficit hyperactivity disorder: risk percentile 99.4%, coverage 100%, PGS003753.
- lifetime major depressive disorder: risk percentile 99.2%, coverage 98%, PGS000139.
- major depression: risk percentile 90.9%, coverage 97%, PGS000145.
- sleeplessness insomnia: risk percentile 88.9%, coverage 100%, PGS001932.
- recent feelings of foreboding: risk percentile 89.3%, coverage 100%, PGS001920.
- addiction risk factors: risk percentile 90.6%, coverage 100%, PGS005215.
Lung Function And Airway Reserve
useful to review
The lung evidence points toward lower respiratory reserve and higher interstitial-lung background. This is most useful for exposure avoidance and for taking persistent breathing symptoms seriously.
Full explanation
The respiratory cluster includes high inherited scores for pulmonary fibrosis and other interstitial lung conditions, alongside low lung-function and forced-breathing measures.
There is also lung-cancer background evidence, while acute lower-respiratory infection evidence is relatively favorable. The overall pattern is still best read as airway-reserve awareness.
This is not a diagnosis of lung disease. It is a reason to be conservative with smoking, vaping, occupational dust, mold, fumes, and poorly ventilated high-pollution settings.
This category becomes worth reviewing if there is persistent cough, breathlessness, wheeze, reduced exercise tolerance, abnormal breathing tests, smoking or vaping exposure, occupational inhalation exposure, or family history of lung fibrosis or early lung disease.
What to watch forAvoid smoking and inhaled irritants, build aerobic capacity gradually, and seek review if persistent cough, breathlessness, reduced exercise tolerance, or exposure history makes this relevant.
Show technical evidence
Risk-score evidence
- lung function: risk percentile 96.1%, coverage 93%, PGS001237.
- forced expiratory volume in 1 second best measure: risk percentile 89.6%, coverage 100%, PGS001918.
- lung cancer: risk percentile 87.8%, coverage 87%, PGS001392.
- unspecified acute lower respiratory infection: risk percentile 14.6%, coverage 86%, PGS000925.
Gallbladder, Bile, And Bilirubin Tendency
useful to review
Gallbladder and bile-related inherited scores are high, with bilirubin context also present. Practical diet rhythm matters more here than restriction.
Full explanation
The digestive-metabolic evidence includes high inherited scores for gallstones, cholelithiasis, cholecystitis, and bilirubin-related traits.
This pattern can matter because gallbladder symptoms are often triggered by meal timing, rapid weight change, and high-fat food loads, though genetics alone cannot say whether gallstones are present.
The useful interpretation is steady digestion support: regular meals, enough fiber, avoiding crash dieting, and keeping large saturated-fat-heavy meals from becoming the default.
This category becomes worth discussing if there is right-upper abdominal pain, pain after rich meals, nausea with fatty foods, pale stools, dark urine, yellowing of the eyes or skin, abnormal liver or bilirubin labs, or a personal or family history of gallstones.
What to watch forKeep meals regular, avoid crash dieting, and review this clinically if upper-right abdominal pain after meals, jaundice signs, or abnormal liver or bilirubin labs appear.
Show technical evidence
Risk-score evidence
- cholecystitis: risk percentile 99%, coverage 88%, PGS000942.
- gallstones: risk percentile 97.5%, coverage 91%, PGS001256.
- cholelithiasis: risk percentile 97.3%, coverage 92%, PGS001174.
- total bilirubin: risk percentile 93%, coverage 100%, PGS001942.
- other disorders of pancreatic internal secretion: risk percentile 84.5%, coverage 79%, PGS001014.
Thyroid And Hormone Signaling Context
useful to review
Thyroid, goiter, sex-hormone, pituitary-hormone, puberty, and pregnancy-context signals cluster together. This is hormone-background context, not proof of current imbalance.
Full explanation
The hormone-related evidence includes high inherited scores for nontoxic multinodular goiter and hypothyroidism-related traits, plus testosterone, estradiol, and pituitary-hormone pathway context.
Individual marker evidence around puberty timing and body-size traits adds to the hormone-development theme. Pregnancy-context evidence is present but should only matter if pregnancy planning or pregnancy history is relevant.
This pattern does not say thyroid hormone, estrogen, testosterone, fertility, or menstrual function is abnormal. It says these systems are worth interpreting with real symptoms and labs rather than genetics alone.
This category becomes worth reviewing if there is neck fullness, thyroid nodules, unexplained fatigue, cold intolerance, hair or skin changes, cycle changes, fertility planning, pregnancy-related questions, or abnormal thyroid or reproductive-hormone labs.
What to watch forUse this as context for thyroid, cycle, fertility, or pregnancy discussions if symptoms, exam findings, family history, or hormone labs make it relevant.
Show technical evidence
Risk-score evidence
- nontoxic multinodular goiter: risk percentile 99.1%, coverage 100%, PGS001814.
- hypothyroidism myxoedema: risk percentile 82.1%, coverage 93%, PGS000965.
- testosterone nmol l: risk percentile 92.3%, coverage 93%, PGS000696.
- testosterone: risk percentile 80.6%, coverage 100%, PGS001914.
- estradiol 212 pmol l: risk percentile 90%, coverage 88%, PGS001182.
- rhesus isoimmunization in pregnancy: risk percentile 92.9%, coverage 100%, PGS002080.
Protein pathway context
- FSHB: predicted level percentile 91.7%, R2 0.6068; pathway context only.
Candidate variants
- ZNF483 rs10980926 GG: snpedia_context.
- ZNF483 rs10441737 TT: snpedia_context.
Heart, Valve, Vessel, And Lipid Context
useful to review
The heart-and-vessel picture is mixed: valve, rhythm, carotid-wall, blood-pressure, and vein signals are present, while clotting and lipid signals are relatively favorable. Medication-safety results matter if statin treatment is ever considered.
Full explanation
The cardiovascular evidence includes inherited context for aortic valve traits, heart electrical timing, carotid-wall thickness, blood-pressure timing, and varicose veins.
That is balanced by favorable inherited scores for blood clots, deep-vein thrombosis, cholesterol, and high cholesterol. Protein pathway context points toward blood-group, immune-adhesion, inflammation, and oxidative-stress biology.
A medication-safety result is relevant specifically if cholesterol-lowering medicine is ever considered, because some statin medicines may need extra care in people with certain inherited drug-transport patterns.
This category becomes worth reviewing if there is chest pain, fainting, palpitations, shortness of breath on exertion, a heart murmur, high blood pressure, abnormal cholesterol labs, clotting history, varicose-vein symptoms, or family history of early heart disease or valve disease.
What to watch forKeep routine blood pressure and lipid context in view, and make sure medication-safety results are checked before starting or changing statin therapy.
Show technical evidence
Risk-score evidence
- p duration: risk percentile 93.9%, coverage 100%, PGS001902.
- mean carotid imtat 120 150 210 240 degrees: risk percentile 85.9%, coverage 100%, PGS001966.
- high blood pressure age at diagnosis: risk percentile 82.7%, coverage 88%, PGS000935.
- varicose veins: risk percentile 86.5%, coverage 100%, PGS001845.
- blood clot or deep vein thrombosis: risk percentile 7.4%, coverage 85%, PGS000931.
- previously blood clot in the legor lung: risk percentile 8.4%, coverage 87%, PGS001278.
Protein pathway context
- ABO: predicted level percentile 6.8%, R2 0.6423; pathway context only.
- ICAM2: predicted level percentile 92.4%, R2 0.5536; pathway context only.
- MST1: predicted level percentile 95.5%, R2 0.6781; pathway context only.
- VNN1: predicted level percentile 1%, R2 0.5856; pathway context only.
Candidate variants
- Variant rs103294 TT: snpedia_context.
- Variant rs10503669 CC: snpedia_context.
Medication-response context
- SLCO1B1: Decreased Function, *15/*37; affected medicines include Simvastatin (myopathy risk), Atorvastatin, Rosuvastatin, Pravastatin.
Kidney Marker Divergence
background
Kidney evidence is split: one chronic-kidney score is high, while several kidney-marker scores look favorable. Real blood pressure, glucose, and kidney labs would decide whether this matters.
Full explanation
The kidney-related evidence is not one-directional. A chronic kidney disease inherited score is high, but urine protein, creatinine, cystatin C, urea, and urine creatinine scores lean favorable.
An individual marker adds blood-urea context, which supports keeping this as a real-lab interpretation issue rather than a diagnosis.
Because glucose-related evidence is also prominent, kidney context is best interpreted through real blood pressure, blood-sugar, and kidney-function results.
This category becomes worth discussing if routine labs show abnormal kidney function, urine protein, high blood pressure, diabetes-related changes, swelling, medication exposures that affect kidneys, recurrent urinary issues, or family history of kidney disease.
What to watch forDo not treat this as kidney disease; use it as context if blood pressure, glucose, urine protein, kidney labs, medication exposure, or family history raises the question.
Show technical evidence
Risk-score evidence
- chronic kidney disease: risk percentile 86.3%, coverage 100%, PGS004004.
- microalbumin in urine: risk percentile 5.5%, coverage 100%, PGS001967.
- cystatin c mg l: risk percentile 9.9%, coverage 93%, PGS000680.
- creatinine: risk percentile 10.8%, coverage 100%, PGS001945.
- urea: risk percentile 7%, coverage 100%, PGS001980.
- creatininein urine: risk percentile 15%, coverage 100%, PGS001944.
Candidate variants
- LOC107986166 rs10937329 TT: snpedia_context.
Blood Count And Immune-Cell Balance
background
Several blood-count and immune-cell signals are high, with some red-cell size and reticulocyte signals low. This is mainly context for interpreting routine blood counts if they are ever abnormal.
Full explanation
The blood evidence includes high inherited scores for red blood cell count, hematocrit, hemoglobin, platelets, neutrophil percentage, monocytes, and basophils.
At the same time, some red-cell size and immature red-cell measures lean low, and individual marker evidence supports blood-cell trait context. That makes this a pattern to interpret with actual blood counts rather than a standalone concern.
The immune-cell part also overlaps with the gut-and-immune inflammation category, which is why this card is framed as supportive context.
This category becomes worth reviewing if routine blood counts show persistently high or low red cells, hemoglobin, platelets, neutrophils, monocytes, or basophils, or if there are unexplained fatigue, headaches, clotting concerns, infections, pregnancy planning questions, or abnormal iron or B-vitamin markers.
What to watch forUse this as context for routine blood-count interpretation, especially if repeated labs show high or low cell counts or pregnancy planning makes blood-type and antibody history relevant.
Show technical evidence
Risk-score evidence
- red blood cellcount: risk percentile 96.4%, coverage 96%, PGS003925.
- haematocrit percentage: risk percentile 93.3%, coverage 100%, PGS001925.
- haemoglobin concentration: risk percentile 83.3%, coverage 92%, PGS001400.
- platelet count: risk percentile 82.2%, coverage 96%, PGS003932.
- neutrophil percentage: risk percentile 99.7%, coverage 96%, PGS003943.
- monocyte count: risk percentile 83.2%, coverage 100%, PGS001968.
Candidate variants
- RCL1 rs10758658 GG: snpedia_context.
- ATP2B4 rs10900585 TT: snpedia_context.
- GPT,LOC101928953 rs1063739 CC: snpedia_context.
Joint And Connective-Tissue Load
background
Joint, arthritis, hand-fascia, limb-pain, and connective-tissue pathway signals suggest paying attention to load management. A favorable knee-arthrosis signal keeps this from being a simple high-risk story.
Full explanation
The musculoskeletal evidence includes high inherited scores for osteoarthritis, broad arthritis, hand-fascia contracture, and limb or joint pain.
There is also connective-tissue and growth-signaling pathway context from genetically predicted proteins, plus body-size markers that can shape biomechanics.
A low knee-arthrosis score is a protective counterpoint, so the best interpretation is not to avoid activity. It is to train progressively, keep joints strong, and adjust volume when pain or stiffness persists.
This category becomes worth reviewing if there is persistent joint swelling, morning stiffness, hand-cord changes, reduced range of motion, recurring tendon pain, injury patterns, or family history of inflammatory arthritis or early joint replacement.
What to watch forBuild strength gradually, keep mobility work simple and consistent, and review persistent swelling, stiffness, hand-cord changes, or recurring joint pain rather than pushing through them.
Show technical evidence
Risk-score evidence
- osteoarthritis: risk percentile 94.3%, coverage 90%, PGS001290.
- arthritis: risk percentile 89.4%, coverage 88%, PGS001135.
- contracture of palmar fascia dupuytren s disease: risk percentile 92.9%, coverage 100%, PGS001880.
- degree bothered by pain in arms legs joints in the past 3 months: risk percentile 80.6%, coverage 88%, PGS001386.
- gonarthrosis arthrosis of knee: risk percentile 3.4%, coverage 90%, PGS001192.
Protein pathway context
- TNN: predicted level percentile 7.8%, R2 0.5604; pathway context only.
- DKKL1: predicted level percentile 4.5%, R2 0.8321; pathway context only.
- FGFR4: predicted level percentile 4.8%, R2 0.6546; pathway context only.
Candidate variants
- PCSK5 rs11144688 GG: snpedia_context.
- SLCO1C1 rs10770705 CC: snpedia_context.
Strength, Lean Mass, And Recovery
background
Body-size, lean-mass, water-mass, and basal-metabolic signals lean low, while waist and body-fat signals are favorable. Training should focus on steady muscle-building, not aggressive dieting.
Full explanation
The body-composition evidence suggests a generally smaller or leaner inherited build, with low body weight, low waist, low fat-free mass, low body water mass, and low basal metabolic rate context.
That can be favorable in some metabolic ways, but it also means performance and resilience may depend heavily on maintaining muscle, fueling training, and allowing recovery.
Connective-tissue pathway signals add a reason to progress gradually rather than relying on sudden spikes in training volume.
This category becomes worth adjusting around if there is repeated injury, stalled strength progress, excessive soreness, poor recovery, unexplained fatigue, unwanted weight loss, appetite changes, or a training plan that feels hard to sustain.
What to watch forPrioritize progressive resistance training, adequate meals around training, and recovery consistency; adjust volume if soreness, fatigue, or joint irritation persists.
Show technical evidence
Risk-score evidence
- whole body fat free mass: risk percentile 0.4%, coverage 96%, PGS003901.
- whole body water mass: risk percentile 0.2%, coverage 96%, PGS003902.
- weight: risk percentile 0.5%, coverage 96%, PGS003898.
- basal metabolic rate: risk percentile 99.9%, coverage 96%, PGS003903.
- impedance of arm: risk percentile 95.4%, coverage 97%, PGS003908.
- height: risk percentile 98.2%, coverage 99%, PGS000758.
Protein pathway context
- TNN: predicted level percentile 7.8%, R2 0.5604; pathway context only.
- DKKL1: predicted level percentile 4.5%, R2 0.8321; pathway context only.
- FGFR4: predicted level percentile 4.8%, R2 0.6546; pathway context only.
Candidate variants
- ZNF483 rs10980926 GG: snpedia_context.
- ZNF483 rs10441737 TT: snpedia_context.
- SLCO1C1 rs10770705 CC: snpedia_context.
Skin, Sun Response, And Visible Aging
background
Sun-related skin-change, non-melanoma skin cancer, keratosis, dermatitis, hair, and facial-aging signals cluster together. The practical takeaway is steady sun protection and prompt review of changing skin findings.
Full explanation
The skin evidence includes high inherited scores for chronic sun-related skin changes, non-melanoma skin cancer, seborrheic keratosis, dermatitis, hair pattern, and visible aging traits.
This is not a statement that skin cancer or a skin condition is present. It is a tendency profile around sun exposure, visible skin aging, and skin reactivity.
Because ancestry metadata is European, sun-response context may be especially practical, but actual skin tone, burn history, outdoor exposure, and family history matter more than genetics alone.
This category becomes worth reviewing if there are changing moles or lesions, non-healing spots, frequent sunburn, significant outdoor exposure, family history of skin cancer, persistent dermatitis, or a skin finding that looks or behaves differently over time.
What to watch forUse consistent sun protection and get changing, bleeding, non-healing, or unusual skin lesions reviewed promptly, especially with high outdoor exposure or family history.
Show technical evidence
Risk-score evidence
- skin changes due to chronic exposure to nonionising radiation: risk percentile 92.6%, coverage 84%, PGS000950.
- non melanoma skin cancer: risk percentile 91%, coverage 89%, PGS001040.
- seborrheic keratosis: risk percentile 85.2%, coverage 89%, PGS001140.
- other dermatitis: risk percentile 84.3%, coverage 89%, PGS000927.
- hair balding pattern: risk percentile 85.3%, coverage 100%, PGS001987.
- facial aging looking about your age: risk percentile 80.4%, coverage 91%, PGS001071.
Screening-Sensitive Cancer Background
background
Several cancer-background scores appear, including colon neoplasm, glioma, lung, and skin, while some other cancer-related scores are favorable. This should reinforce routine screening and symptom-aware review, not create alarm.
Full explanation
The cancer-related evidence is mixed. Colon neoplasm, glioma, lung cancer, and non-melanoma skin cancer scores appear in the high tail, while early-onset colorectal, triple-negative breast, and lymphocytic leukemia signals are relatively favorable.
Protein pathway context overlaps with growth signaling and immune activation, but this is still background evidence rather than a cancer prediction.
The most practical interpretation is to keep age-appropriate screening, skin awareness, and symptom-led medical review in place without assuming anything is present.
This category becomes worth discussing if there is bowel bleeding or persistent bowel change, unexplained neurological symptoms, changing skin lesions, persistent cough, smoking or inhalation exposure, strong family history, or questions about when standard screening should begin.
What to watch forKeep routine age-appropriate screening and review persistent bowel, neurological, skin, or respiratory changes in the normal medical way, especially with family history or exposure context.
Show technical evidence
Risk-score evidence
- benign neoplasm of colon: risk percentile 97.4%, coverage 100%, PGS001811.
- non melanoma skin cancer: risk percentile 91%, coverage 89%, PGS001040.
- lung cancer: risk percentile 87.8%, coverage 87%, PGS001392.
- lymphocytic leukemia: risk percentile 4.1%, coverage 99%, PGS000077.
Protein pathway context
- FGFR4: predicted level percentile 4.8%, R2 0.6546; pathway context only.
- CD70: predicted level percentile 92.5%, R2 0.5346; pathway context only.
Medication Safety
Genes below have pharmacogenomic phenotypes that may affect drug choice or dose review. Use this as a clinical discussion aid, not as a standalone prescribing instruction.
CYP3A5
POOR METABOLIZER
*3/*3
Affected drugs: Tacrolimus, Sirolimus
SLCO1B1
DECREASED FUNCTION
*15/*37
Affected drugs: Simvastatin (myopathy risk), Atorvastatin, Rosuvastatin, Pravastatin
UGT1A1
INDETERMINATE
*1/*80
Affected drugs: Irinotecan, Atazanavir
CYP2B6
INTERMEDIATE METABOLIZER
*1/*9
Affected drugs: Efavirenz, Bupropion, Methadone
ABCG2
DECREASED FUNCTION
rs2231142 reference (G)/rs2231142 variant (T)
Affected drugs: See CPIC guidance
This report comes from consumer microarray data with statistical imputation. Confirm clinically before changing prescriptions.